A Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder
|
|
- Rose Fisher
- 5 years ago
- Views:
Transcription
1 A Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder Maria Paola Pascali, Giovanni Mosiello,* Armando Marciano, Maria Luisa Capitanucci, Antonio Maria Zaccara and Mario De Gennaro From the Department of Nephro-Urology, Urodynamics and NeuroUrology Unit, Bambino Gesù Pediatric Hospital, Rome, Italy Abbreviations and Acronyms BoNTA botulinum toxin type A CIC clean intermittent catheterization NBD neurogenic bladder dysfunction Study received ethical committee approval. * Corresponding author: Neurourology Unit, Bambino Gesù Pediatric Hospital, Piazza S Onofrio 4, Rome, Italy (telephone: ; FAX: ; mosiello@opbg.net). Purpose: Botulinum toxin type A has revolutionized the treatment of neurogenic bladder dysfunction. The original injection technique used a rigid cystoscope and a flexible collagen needle. To date botulinum toxin type A injection techniques have not been standardized. We present our experience in pediatric patients using a new flexible injection system. Materials and Methods: We treated 24 patients 3.8 to 17.5 years old who had neurogenic bladder dysfunction with botulinum toxin type A bladder and/or sphincter injection using a rigid cystoscope and the new N-DO endo-injector needle system. Another 24 patients 3.6 to 17.8 years old were treated with a 3.7Fr standard flexible needle and served as controls. Operative time, hospital stay, complications and efficacy were considered. Selection criteria and treatment were the same in the 2 groups. The 10 IU/kg dose was determined according to European Association of Urology guidelines. Results: All patients received botulinum toxin type A bladder injection while 11 patients in the endo-injector group and 5 controls also received urethral injection. In the endo-injector needle and control groups average operative time was 12.4 and 17.3 minutes for the bladder, and 5.1 and 10.1 minutes for the urethra, respectively (each p 0.05). All patients were discharged home the day after the procedure. No complications were observed. Urodynamics revealed an average maximum detrusor pressure decrease of 25 and 21 cm H 2 O, and an average bladder capacity increase of 75 and 80 ml in the endo-injector and control groups, respectively (p not significant). Conclusions: While retaining efficacy, the endo-injector needle technique appears to be more rapid than the standard procedure for botulinum toxin type A injection for neurogenic bladder dysfunction. Whether patients may be treated with sedation only remains to be clarified. Key Words: urinary bladder, neurogenic; urethra; botulinum toxin type A; injections; endoscopy AS in adults, BoNTA injection is a well established method to treat NBD in children. 1,2 It is currently an alternative when standard therapy with antimuscarinics and CIC fails. 3 Bladder injection techniques have not been standardized to date. 4 In the original application for NBD BoNTA was administered through a rigid cystoscope. Less invasive techniques have already been reported, such as the Dasgupta technique, which uses ultrafine injection needles via a flexible cystoscope with the patient under local anesthesia and injections evenly distributed in the bladder wall apart from the trigone /11/ /0 Vol. 185, , June 2011 THE JOURNAL OF UROLOGY Printed in U.S.A by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. DOI: /j.juro
2 SIMPLIFIED BOTULINUM TOXIN INJECTION TECHNIQUE FOR NEUROGENIC BLADDER 2559 Figure 1. Map of bladder injections Our experience started in 1997 with BoNTA for neuropathic bladder secondary to myelomeningocele, occult spina bifida and spinal cord injury. The urodynamic patterns included were overactive bladder with dyssynergia or a high pressure, low compliant bladder in patients who did not satisfactorily respond to anticholinergics. Although the original technique described by Schurch et al of performing injections at multiple sites using a rigid cystoscope and flexible needle is long established, 5 since 2003 we have defined our personal technique and treatment protocol. In this study we evaluated the benefit of a flexible needle system 6 with a rigid cystoscope to inject BoNTA in a pediatric population. MATERIALS AND METHODS Informed consent was obtained from patients and/or parents entering the study. The study was done in accordance with the Declaration of Helsinki in a protocol for the use of BoNTA in children with NBD, as approved by our ethical committee. All patients were on CIC, and had no response to standard treatment with anticholinergics and no vesicoureteral reflux. Study exclusion criteria were age less than 2 years, previous lower urinary tract surgery, unstable neurological status or urinary tract infections. In all patients had urodynamic examination was performed 3 months before treatment and 3 to 6 months thereafter. All examinations were done according to International Children s Continence Society standards. 7 Incontinence was evaluated before and after treatment based on pad use and patient diary reports. To define changes in dry episodes or dryness between catheterizations before and after BoNTA treatment we also graded dryness status as 0 completely dry, 1 no pads and urine leakage only during the night, 2 usually no pads but 1 or more urinary leakage episodes during the day and 3 pads used due to urinary leakage almost every time. 5,8 The effectiveness of continence treatment was established at the 3-month follow-up and considered cure or improvement in dryness. All patients were treated with BoNTA at dose of 10 IU/kg (maximum 300 IU Botox ). Technique Procedures consisted of multiple injections into the detrusor following vertical virtual lines, including 2 starting 0.5 to 1 cm above and lateral to the urethral orifices, and the others in the middle (fig. 1), sparing the trigone and blood vessels. A rigid cystoscope was used with the patient under general anesthesia and the procedure was always done in the operating room. Injections were made preferably into a trabeculated muscle bundle by injecting 1 ml (10 IU/1 ml saline solution) at each site with an injection depth of 3 to 5 mm and a full bladder. 9,10 When BoNTA injections were performed on the bladder wall or the sphincter, the same dose of 10 IU/kg was used, including 8 IU/kg for the bladder and 2 IU/kg for the urethra. Transurethral injections were performed deeply at the level of the external striated sphincter at the 3, 6 and 9 o clock positions. Postoperatively in all patients a Foley catheter was left in situ for 12 hours and CIC was started thereafter. Feeding started 2 hours after the end of the operative procedure with intravenous fluid administration for 12 hours. To exclude side effects, vital signs (temperature, heart rate and oxygen saturation) were recorded in all patients. Patients were discharged home the following day. Antibiotics were prescribed for 7 days and anticholinergics were discontinued in all after 2 weeks. Before the procedures patients were allocated into 2 treatment groups. Group 1 was treated with the new N-DO endo-injector system with a 5Fr flexible catheter needle that is adjustable in curving geometry and length (fig. 2). Group 2 was treated with a classic 3.7Fr flexible collagen needle. The N-DO system is a new endo-injector with a progressively curving, retractable needle that has some technical advantages. This 5Fr flexible needle enables easier injection at different areas in a controlled Figure 2. A, endo-injector system with needle length handle control. B, retractable needle.
3 2560 SIMPLIFIED BOTULINUM TOXIN INJECTION TECHNIQUE FOR NEUROGENIC BLADDER Figure 3. Endoscopic procedure. A, needle retracted before injection. B, injecting trabeculated muscle bundles. mode due to the slider on the handle, which allows the operator to extend the needle to the desired length, retract it after injection and control injection depth as desired since needle length can be adjusted 2 mm at a time. This is useful for bladder injection, for which it is possible to define a standard 4 mm depth (2 steps). In contrast, for urethral injection it is possible to inject more deeply at the external urethral sphincter level. Needle curvature provides easier access to areas where injection is usually difficult, such as the lateral or superior bladder wall, or the bladder neck, and also makes it possible to always inject on the trabeculated muscle bundle. The system keeps the needle visible at all times for safety, effectiveness, precision and control (fig. 3). Retracting the needle during bladder inspection may avoid unwanted bladder wall puncture, minimizing the risk of complications even in inexperienced hands. To evaluate results in the 2 groups we compared endoscopic procedure duration, hospital stay, complications and effectiveness with respect to continence status, and preoperative and postoperative urodynamic records. Data were analyzed using standard statistical Microsoft Excel with the Student t, chi-square and Fisher exact tests with p 0.05 considered statistically significant. RESULTS A total of 48 patients were enrolled in the study and assigned to group 1 24 who were 3.8 to 17.5 years old with the endo-injector needle system and control group 2 24 who were 3.6 to 17.8 years old with the standard 3.7Fr collagen needle. All patients underwent bladder wall treatment while 11 in group 1 and 5 in group 2 were also treated on the bladder neck and urethra. In groups 1 and 2 complete mean operative time was 12.4 and 17.3 minutes for the bladder, and 5.1 and 10.1 minutes for the urethra, respectively (each p 0.05). All procedures were done in the operating room using general anesthesia. Postoperative management was the same in the 2 groups. Hospital stay did not differ in the groups and all patients were discharged home the day after the procedure with no complications. Procedure effectiveness in terms of urodynamic data, dryness rate improvement/cure and mean duration of effect showed no statistically significant difference in the 2 groups (see table). DISCUSSION Since the first report in 2002 by Schulte-Baukloh on 17 patients with NBD related to spina bifida, 11 BoNTA has demonstrated its effectiveness in the pediatric population. 11 There has been increasing evidence of BoNTA use in children with NBD during the years Nevertheless, the injection technique has not been standardized in children or adults. Although BoNTA administration using a flexible or rigid cystoscope has been reported with significant improvement in symptoms and urodynamic parameters, 19,20 to our knowledge no comparative studies have defined the advantages of different techniques. Originally BoNTA was administered using a rigid cystoscope and a collagen flexible needle. Subsequently a minimally invasive technique using a flexible cystoscope 21 became popular in adults, in whom BoNTA administration is often performed using local anesthesia or sedation. 22 In the pediatric population there is no clear consensus on the optimal dose, injection number and sites or cystoscope type. The amount of Botox injected into the bladder was 5 to 12 IU/kg with a Urodynamic and clinical results Group 1 Group 2 Mean change: Detrusor pressure (cm H 2 O) Bladder capacity (ml) % Incontinence cure/improvement Mean mos benefit (range) 8.2 ( ) 8.1 ( )
4 SIMPLIFIED BOTULINUM TOXIN INJECTION TECHNIQUE FOR NEUROGENIC BLADDER 2561 maximal dose of 360 IU, usually at 30 injection sites (range 10 to 50) of 10 IU/ml (range 10 kg/20 ml to 12/15). The most commonly used Botox dose is 10 IU/kg/ml with a maximal dose of 300 IU and a maximum of 30 injections. In all pediatric studies injection as been done directly into detrusor, sparing the trigone, using a rigid cystoscope and general anesthesia, as in our experience. For sphincteric/bladder neck applications the injections are usually performed at the 3, 6 and 9 o clock positions transurethrally or transperineally with a dose of 50 to 100 IU depending on patient age and body weight. 1,2 Instrument choice is related to instrument availability and individual experience with pediatric urologists mainly using a rigid instead of a flexible cystoscope. In 2003 we started to use the N-DO injection system with a 5Fr 24 gauge needle instead of the flexible collagen or metallic 3.7Fr 23 gauge needle that we used previously, always with a rigid cystoscope, to treat NBD with BoNTA. We performed combined bladder and urethral injections in some children who could not or refused to perform CIC without any obvious beneficial effects on dry episodes. BoNTA urethral/bladder neck injections produce transient chemical sphincterotomy. It can be used safely for detrusor-sphincter dyssynergia, as in adolescents with partially preserved micturition who prefer to use abdominal straining to void instead of CIC due to common transient refusal of the catheterization treatment regimen, or in severely disabled obese patients as an alternative to female urethral over distension or male endoscopic external sphincterotomy 23 in all in whom there is no clinical indication to create a continent catheterizable stoma. In our experience we have always used the same technique and protocol to inject the bladder and urethra with same dose (10 IU/kg), dilution (10 IU/ ml) at the same site, sparing the trigone and following rows in the bladder, and at the 3, 6 and 9 o clock positions in the urethra. We evaluated the theoretical advantages of a new needle. Although we noted equal effectiveness and safety, our results showed a significant difference in the 2 groups in operative time (p 0.05). This decreased operative time seems to be useful for 2 main reasons. 1) It encourages combined intradetrusor and intrasphincter injections, which may achieve better results for upper urinary tract protection and maybe relative dryness, as suggested. 24 2) It makes BoNTA amenable to administration using local anesthesia or using sedation as in adults, in the outpatient setting, decreasing hospital stay and costs. 25 CONCLUSIONS Today BoNTA administration is a well established treatment for NBD in children. Our technique with this injection system seems to be safe and effective, encouraging more correct treatment of the bladder or urethra with no morbidity. Decreased operative time may allow BoNTA to be administrated using local anesthesia or sedation even in the pediatric population, reducing hospital stay and costs. ACKNOWLEDGMENTS Dr. Stefano Canu assisted with statistical analysis. REFERENCES 1. Gamé X, Mourdacade P, Chartier-Kastler E et al: Botulinum toxin-a intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder. A systematic literature review. J Pediatr Urol 2009; 5: Dasgupta R and Murphy FL: Botulinum toxin in pediatric urology: a systematic literature review. Pediatr Surg Int 2009; 25: Hernandez RD, Hurwitz RS, Foote JE et al: Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol 1994; 152: Apostolidis A, Dasgupta P, Denys P et al: Recommendations on the use of Botulinum Toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunction: a European consensus report. Eur Urol 2009; 55: Schurch B, Sthohrer M, Kramer G et al: Botulinum toxin type A for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergics drugs? Preliminary results. J Urol 2000; 164: Brausi AM, Verrini G, De Luca G et al: The use of local anaesthesia with N-DO injector for transurethral resection of bladder tumors: preliminary results and cost effectiveness analysis. Eur Urol 2007; 52: Nevéus T, von Gontard A, Hoebeke P et al: The standardization of terminology of lower urinary tract function in children and adolescent: report from the Standardisation Committee of the International Children s Continence society. J Urol 2006; 176: Kuo HC: Urodynamic evidence of effectiveness of botulinum toxin-a injection in the treatment of detrusor overactivity refractory to anticholinergics agents. Urology 2004; 63: Schulte-Baukloh H, Knispel HH et al: A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005; 95: Apostolidis A, Dasgupta R, Fowler CJ et al: Re: A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005; 95: Schulte-Baukloh H, Schobert MT, Stolze T et al: Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002; 59: Schulte-Baukloh H, Michael T, Sturzebecher B et al: Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003; 44: Riccabona M, Koen M, Schindler M et al: Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with my-
5 2562 SIMPLIFIED BOTULINUM TOXIN INJECTION TECHNIQUE FOR NEUROGENIC BLADDER elomeningocele with detrusor hyperreflexia. J Urol 2004; 171: Schulte-Baukloh H, Knispel HH, Stolze T et al: Repeated botulinum-a toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005; 66: Akbar M, Abel R, Seyler TM et al: Repeated botulinum-a toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 2007; 100: Altaweel W, Jednack R, Bilodeau C et al: Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 2006; 175: Kajbafzadeh AM, Moosavi S, Tajik P et al: Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology 2006; 68: Neel KF, Soliman S, Salem M et al: Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder. J Urol 2007; 78: Schurch B, de Seze M, Denys P et al: Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-mo study. J Urol 2005; 174: Apostolidis A, Kalsi V, Gonzales G et al: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-a toxin. J Urol 2005; 174: Harper M, Popat R, Dasgupta R et al: A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003; 92: Smith PC and Chancellor MB: Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites injection. J Endourol 2005; 19: de Jong TPM, Chrzan R, Klijn AJ et al: Treatment of neurogenic bladder in spina bifida. Pediatr Nephrol 2008; 23: Safari S, Jamall S, Habibollahi P et al: Intravesical injection of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. Urology 2010; 76: Sangster P and Kalsi V: Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity. BJU Int, suppl., 2008, 102: 17.
INTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE
PEDIATRIC UROLOGY INTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE ABDOL-MOHAMMAD KAJBAFZADEH, SHAHRAM MOOSAVI,
More informationHospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationHasheminejad Kidney Center (HKC), Iran University of Medical Sciences (IUMS), Tehran, Iran
ORIGINAL ARTICLE Vol. 43 (6): 1122-1128, November - December, 2017 doi: 10.1590/S1677-5538.IBJU.2016.0622 Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity:
More informationReview Article Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 763159, 6 pages doi:10.5402/2012/763159 Review Article Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum
More informationAdverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome
EUROPEAN UROLOGY 58 (2010) 919 926 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor
More informationCASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1
1 CASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1 35 years old man, who previously has been completely healthy, was shot twice in the neck
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1729 1735 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationRecommandations de prise en charge des vessies neurogènes EAU 2006
Annexe 4-1 Recommandations de prise en charge des vessies neurogènes EAU 2006 (Version courte) 685 686 GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E.
More informationThe Successful and Novel Treatment of Non-Neurogenic Detrusor- External Sphincter Dyssynergia (DESD) with Botulinum Toxin A
original article The Successful and Novel Treatment of Non-Neurogenic - External Sphincter Dyssynergia (DESD) with Botulinum Toxin A Tricia LC Kuo, MBBS, MRCSEd, M Med (Surg), FAMS, Lay Guat Ng, MBBS,
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationMultiple Sclerosis. Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
Queen Square Uro-neurology course, London, UK 20 th -21 st October 2016 Multiple Sclerosis Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
More informationNeurogenic Bladder. Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, Eric Levey, M.D.
Neurogenic Bladder Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, 2018 Eric Levey, M.D. Pediatrics & Neurodevelopmental Disabilities Chief Medical Officer,
More informationeuropean urology 53 (2008)
european urology 53 (2008) 275 287 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology Botulinum Toxin A (Botox W ) Intradetrusor Injections in Adults with
More informationTuesday 24 June Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart
Tuesday 24 June 10.30 11.30 Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart P001 Can oral antibiotic prophylaxis reduce the rate of infection after conventional urodynamic studies?
More informationOutcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder Michael K. Flynn,* Cindy L. Amundsen, MaryAnn Perevich, Fan Liu and George D. Webster
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationBotulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction
European Urology European Urology 48 (2005) 984 990 Botulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction Heinrich Schulte-Baukloh
More informationUK Consensus on Bladder Management in MS
Continence Care Forum Annual Conference UK Consensus on Bladder Management in MS Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Association of British Neurologists
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationOnabotulinumtoxin A for Treating Overactive/Poor Compliant Bladders in Children and Adolescents with Neurogenic Bladder Secondary to Myelomeningocele
Toxins 2013, 5, 16-24; doi:10.3390/toxins5010016 Article OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Onabotulinumtoxin A for Treating Overactive/Poor Compliant Bladders in Children and
More informationNeuropathic Bladder. Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014
Neuropathic Bladder Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014 Plan Physiology- bladder and sphincter behaviour in neurological disease Clinical consequences of Symptoms
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Text update pril 2014) J. Pannek (co-chair), B. Blok (co-chair), D. Castro-Diaz, G. del Popolo, J. Groen, G. Karsenty, T.M. Kessler, G. Kramer, M. Stöhrer Eur Urol 2009 Jul;56(1):81-8
More informationEMR template and postprocedure notes
EMR template and postprocedure notes Sample autopopulated text to create a BOTOX injection procedure report Information gathered from market research. These considerations are for reference only and should
More informationCHAPTER 1 INTRODUCTION
Introduction 1 CHAPTER 1 INTRODUCTION 8 Introduction Spina bifida is a congenital defect of the spine in 1-3 out of 1000 live born children 1 and still is one of the most common serious congenital malformations.
More informationPhysiology & Neurophysiology of lower U.T.
Physiology & Neurophysiology of lower U.T. Classification of voiding dysfunction Evaluation of a child with voiding dysfunction Management Storage Ø Adequate volume of urine Ø At LOW pressure Ø With NO
More information6 Page Male Incontinence Booklet 10/09/ :44 Page 1. The Natural Non-Surgical Option for Male Urinary Incontinence
6 Page Male Incontinence Booklet /9/ :44 Page The Natural Non-Surgical Option for Male Urinary Incontinence 6 Page Male Incontinence Booklet /9/ :44 Page Stress Urinary Incontinence - A Stressful Prospect
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationExperience with Different Botulinum Toxins for the Treatment of Refractory Neurogenic Detrusor Overactivity
Neurourology Botulinum Toxins for Refractory Detrusor Overactivity International Braz J Urol Vol. 36 (1): 66-74, January - February, 2010 doi: 10.1590/S1677-55382010000100011 Experience with Different
More informationIntermittent self-catheterisation (ISC) Information for patients Spinal Injuries
Intermittent self-catheterisation (ISC) Information for patients Spinal Injuries page 2 of 12 What is clean intermittent self-catheterisation (CISC)? Urinary catheterisation is a procedure used to drain
More informationFemale Epispadias Repair
hoofdstuk 07 08-03-2001 15:25 Pagina 89 Female Epispadias Repair Female epispadias repair: a new 1-stage technique CHAPTER 7 Tom P.V.M de Jong, Pieter Dik and Aart J. Klijn Journal of Urology 2000, 164,
More informationIntravesical Botox Injections
Intravesical Botox Injections Department of Urology Patient Information What What is is Botox? Botox? Botox or Botulinum Type-A is toxin produced by bacteria called Clostridium Botulinum. It is given intravesically
More informationProspective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder
Original Article Prospective randomized trial of vs botox in the treatment of idiopathic overactive bladder Waleed AlTaweel, Alaa Mokhtar, Danny M. Rabah 1 King Faisal Specialist Hospital and Research
More informationManagement of neurogenic bladder in children. In: Guidelines on paediatric urology.
Complete Summary GUIDELINE TITLE Management of neurogenic bladder in children. In: Guidelines on paediatric urology. BIBLIOGRAPHIC SOURCE(S) Management of neurogenic bladder in children. In: Tekgul S,
More informationNEUROMODULATION FOR UROGYNAECOLOGISTS
NEUROMODULATION FOR UROGYNAECOLOGISTS Introduction The pelvic floor is highly complex structure made up of skeletal and striated muscle, support and suspensory ligaments, fascial coverings and an intricate
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationEFFECTS OF BOTULINUM TOXIN A INJECTIONS IN SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA
J Rehabil Med 2016; 48: 683 687 ORIGINAL REPORT EFFECTS OF BOTULINUM TOXIN A INJECTIONS IN SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA Maping Huang, PhD 1,
More informationBotulinum Toxin Treatment for Overactive Bladder: Efficacy, Mechanism of Action, Techniques and Practical Tips W16, 15 October :00-17:00
Botulinum Toxin Treatment for Overactive Bladder: Efficacy, Mechanism of Action, Techniques and Practical Tips W16, 15 October 2012 14:00-17:00 Start End Topic Speakers 14:00 14:15 Introduction Mohammad
More informationAccepted Manuscript. Does intraoperative success predict outcome in the treatment of urethral sphincter insufficiency with bulking agent?
Accepted Manuscript Does intraoperative success predict outcome in the treatment of urethral sphincter insufficiency with bulking agent? Niklas Pakkasjärvi, Seppo Taskinen PII: S1477-5131(18)30005-6 DOI:
More informationBOTULINUM TOXIN IN LOWER URINARY TRACT
BOTULINUM TOXIN IN LOWER URINARY TRACT Selcuk Yucel, MD Professor in Urology and Pediatric Urology Acibadem University School of Medicine Department of Uroloy and Pediatric Urology Acibadem University
More informationHow to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina
Reviews How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina Mikolaj Przydacz A F, Tomasz Golabek A,E,F, Piotr Chlosta A,E,F Department of Urology, Jagiellonian
More informationOnabotulinumtoxinA for the treatment of overactive bladder
OnabotulinumtoxinA for the treatment of overactive bladder Clin. Invest. (2014) 4(3), 281 286 OnabotulinumtoxinA has recently been granted a license for use in overactive bladder (OAB). This review assesses
More informationTHE EFFECT OF ENDOSCOPIC INJECTIONS OF DEXTRANOMER BASED IMPLANTS ON CONTINENCE AND BLADDER CAPACITY: A PROSPECTIVE STUDY OF 31 PATIENTS
0022-5347/02/1684-1863/0 Vol. 168, 1863 1867, October 2002 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2002 by AMERICAN UROLOGICAL ASSOCIATION, INC. DOI: 10.1097/01.ju.0000029638.43807.5b THE EFFECT
More informationAn Effective Day Case Treatment Combination for Refractory Neuropathic Mixed Incontinence
Neurourology A Day Case Treatment for Neuropathic Mixed Incontinence International Braz J Urol Vol. 34(1): 63-72, January - February, 2008 An Effective Day Case Treatment Combination for Refractory Neuropathic
More informationeuropean urology 50 (2006)
european urology 50 (2006) 806 810 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Successful Treatment with Intradetrusor Botulinum-A Toxin for Urethral Urinary
More informationThe Management of Female Urinary Incontinence. Part 1: Aetiology and Investigations
The Management of Female Urinary Incontinence Part 1: Aetiology and Investigations Dr Oseka Onuma Gynaecologist and Pelvic Reconstructive Surgeon 4 Robe Terrace Medindie SA 5081 Urinary incontinence has
More informationIn Utero Closure of Myelomeningocele Does Not Improve Lower Urinary Tract Function
In Utero Closure of Myelomeningocele Does Not Improve Lower Urinary Tract Function Nora G. Lee, Pablo Gomez, Vikrant Uberoi, Paul J. Kokorowski, Shahram Khoshbin, Stuart B. Bauer and Carlos R. Estrada*
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Limited text update March 2015) B. Blok (Co-chair), J. Pannek (Co-chair), D. Castro Diaz, G. del Popolo, J. Groen, T. Gross (Guidelines ssociate), R. Hamid, G. Karsenty, T.M.
More informationImpact of urethral catheterization on uroflow during pressure-flow study
Research Report Impact of urethral catheterization on uroflow during pressure-flow study Journal of International Medical Research 2016, Vol. 44(5) 1034 1039! The Author(s) 2016 Reprints and permissions:
More informationPost-Otis Incontinence
hoofdstuk 04 08-03-2001 15:29 Pagina 45 Post-Otis Incontinence The treatment of post-urethrotomy incontinence in pediatric and adolescent female subjects CHAPTER 4 Tom P.V.M. de Jong, Jan D. van Gool,
More informationEUROPEAN UROLOGY 57 (2010)
EUROPEAN UROLOGY 57 (2010) 891 896 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory
More informationBotulinum Toxin Injection: A Review of Injection Principles and Protocols
Review Article Botulinum Toxin Injection International Braz J Urol Vol. 33 (2): 132-141, March - April, 2007 Botulinum Toxin Injection: A Review of Injection Principles and Protocols David E. Rapp, Alvaro
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationOnabotulinumtoxin - A Injections for the Treatment of Neurogenic Detrusor Overactivity
Onabotulinumtoxin - A Injections for the Treatment of Neurogenic Detrusor Overactivity Raluca Borcăiaș 1, S. Rașcu 1,2, V. Jinga 1,2, D. Mischianu 1,3, A. Manu-Marin 4 1 Carol Davila University of Medicine
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2017) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler Guidelines Associates:
More informationAdult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline
Adult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline TARGET POPULATION Eligibility Decidable (Y or N) Inclusion
More informationEfficacy of High-frequency Magnetic Stimulation of the Sacral Root in Patients with Urinary Incontinence Following a Radical Prostatectomy
LUTS (2011) 3, 10 14 ORIGINAL ARTICLE Efficacy of High-frequency Magnetic Stimulation of the Sacral Root in Patients with Urinary Incontinence Following a Radical Prostatectomy Nobuyuki KAI, 1 Masakazu
More informationABSTRACT ORIGINAL RESEARCH
Adv Ther (2013) 30:819 833 DOI 10.1007/s25-013-0054-z ORIGINAL RESEARCH OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationBladder Dysfunction in Multiple Sclerosis. by Nancy J. Holland, EdD, RN and Nancy C. Reitman, MA, RN
Clinical Bulletin Information for Health Professionals Bladder Dysfunction in Multiple Sclerosis by Nancy J. Holland, EdD, RN and Nancy C. Reitman, MA, RN Effective bladder management strategies make it
More informationBlue Ridge Urogynecology
Surgery for Stress Urinary Incontinence Surgery has proved to be a very effective treatment for stress incontinence. The best surgical procedures improve or cure the incontinence in 85 to 90 percent of
More informationCase Based Urology Learning Program
Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 23 CBULP 2011 077 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,
More informationBotulinum toxin-a for the treatment of overactive bladder: UK contributions
473096URO6210.1177/2051415812473096Journal of Clinical UrologySeth et al. 2013 Original Article Botulinum toxin-a for the treatment of overactive bladder: UK contributions Journal of Clinical Urology 6(2)
More informationA review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals
264 Central European Journal of Urology REVIEW PAPER FUNCTIONAL UROLOGY A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals Cristian Persu 1, Emmanuel Braschi 2, John Lavelle
More informationThe new ICCS terminology J Urol 176, , 2006
The new ICCS terminology J Urol 176, 314-324, 2006 The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Report from the Standardisation Committee of the International
More informationUrodynamics in Neurological Lower Urinary Tract Dysfunction. Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne
Urodynamics in Neurological Lower Urinary Tract Dysfunction Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne Learning Objectives Review functional neurology relevant to lower
More informationREVIEW ARTICLE. Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder
76 REVIEW ARTICLE Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder Marius Alexandru Moga, 1 Simona Banciu, 2 Oana Dimienescu, 3 Nicusor-Florin Bigiu, 4 Ioan Scarneciu 5 Abstract
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationStimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury. Original Policy Date
MP 7.01.58 Stimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury Medical Policy Section Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationRetrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder
European Urology European Urology 45 (2004) 240 244 Retrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder A. Raes a,, P. Hoebeke b, I. Segaert a, E. Van
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2016) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler. Guidelines Associates:
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationRobotic Appendicovesicostomy
Robotic Appendicovesicostomy Cheryl Baxter, MSN,RN,CPNP Daniel DaJusta, MD Kristina Booth, MSN,RN,FNP Roadmap for Presentation Part 1 Pre-surgical/historical neurogenic bladder- Baxter Part 2 Robotic appendicovesicostomy/
More informationThis Special Report supplement
...INTRODUCTION... Overactive Bladder: Defining the Disease Alan J. Wein, MD This Special Report supplement to The American Journal of Managed Care features proceedings from the workshop, Overactive Bladder:
More informationGUIDELINES ON URINARY INCONTINENCE
GUIDELINES ON URINARY INCONTINENCE 9 J. Thüroff, (chairman), P. Abrams, J-T. Andersen, W. Artibani, E. Chartier-Kastler, C. Hampel, M. Hohenfellner, T. Tammela, Ph. van Kerrebroeck Introduction The condition
More informationManagement of the Urinary Tract in Spina Bifida Cases Varies With Lesion Level and Shunt Presence
Neuropathic Bladder Management of the Urinary Tract in Spina Bifida Cases Varies With Lesion Level and Shunt Presence Peter Metcalfe,* Darren Gray and Darcie Kiddoo From the Division of Pediatric Surgery,
More informationDATE: 24 September 2014 CONTEXT AND POLICY ISSUES
TITLE: The Use of the Electromotive Drug Administration System in Patients with Overactive Bladder: A Review of the Clinical Effectiveness, Safety, and Cost- Effectiveness DATE: 24 September 2014 CONTEXT
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationO (P =.005) in the NDO group and from ± 9.92 cmh 2. O to ± cmh 2
MISCELLANEOUS Success Rate and Patients' Satisfaction Following Intradetrusor Dysport Injection in Patients with Detrusor Overactivity: A Comparative Study of Idiopathic and Neurogenic Types of Detrusor
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationAn Approach to Children with Neurogenic Bladder Dysfunction
Author query: (1) Plz provide citations in text for tables 29.1 to 29.4 and figures 29.1 and 29.2; (2) Plz check the highlighted text for its accuracy 29 CHAPTER An Approach to Children with Neurogenic
More informationDepartment of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi , India
Original Article A Clinical and Urodynamic Study on the Effects of Oral Tolterodine on Serial Alterations in Neurogenic Detrusor Overactivity vis-à-vis Oral Oxybutynin in Children (Existing Oxybutynin
More informationClinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg148
Urinary incontinence in neurological disease: assessment and management Clinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg148 NICE 2018. All rights reserved. Subject to Notice of rights
More informationGOVINDARAJ N. RAJKUMAR, DOUGLAS R. SMALL, ABDUL W. MUSTAFA and GRAEME CONN Department of Urology, Southern General Hospital, Glasgow, UK
Original Article BTXA IN DETRUSOR FOR REFRACTORY IDIOPATHIC DOA RAJKUMAR et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of
More informationUSE OF BOTOX IN BLADDER DISORDERS
USE OF BOTOX IN BLADDER DISORDERS AN INFORMATION LEAFLET Written by: Department of Urology January 2017 Stockport: 0161 419 5698 Web site: w w w. s t o c k p o r t. n h s. u k Tameside: 0161 922 6696/6698
More informationThe Need for Augmentation after Bladder Exstrophy Closure
Annals of Pediatric Surgery Vol 5, No 2, April 2009, PP 109-114 Original Article The Need for Augmentation after Bladder Exstrophy Closure Mohammed Abdel-Latif Ayad, Ehab El-Shafei, Hatem Abdel-Kader,
More informationComparison of the Effects by Obybutynin and Tolterodine on Spina Bifida Patients: A Pilot Crossover Study
LUTS (2011) 3, 99 103 ORIGINAL ARTICLE Comparison of the Effects by Obybutynin and Tolterodine on Spina Bifida Patients: A Pilot Crossover Study Akihiro KANEMATSU, 1,2 Kazuyoshi JOHNIN, 2,3 Koji YOSHIMURA,
More informationurethral stricture recurrence after internal urethrotomy.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 9-, p-issn: 9-.Volume, Issue Ver. II (Nov. ), PP - www.iosrjournals.org Effects of Intralesional Triamcinalone injection following Internal
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationI-STOP TOMS Transobturator Male Sling
I-STOP TOMS Transobturator Male Sling The CL Medical I-STOP TOMS sling for male stress urinary incontinence was developed in France where it is widely used and is the market leader. It is constructed with
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More information